Defining the underlying pathology of corticobasal syndrome using clinical features and biomarkers. | ScholarDeck

Paper

Defining the underlying pathology of corticobasal syndrome using clinical features and biomarkers.

New research · Neurology

Brain : a journal of neurology · 4w

Cohort studyBrain : a journal of neurology· Aug 2026

Defining the underlying pathology of corticobasal syndrome using clinical features and biomarkers.

David P Vaughan, Marte Theilmann Jensen, Raquel Real … Huw R Morris

Read paper

Movement DisordersCohort studyDiagnosisQ1IF 9.7

Younger onset age helps identify Alzheimer's pathology in corticobasal syndrome

Defining the underlying pathology of corticobasal syndrome using clinical features and biomarkers.

David P Vaughan … Huw R Morris

Brain · Aug 2026 · Q1 in Neurology

Background

Corticobasal degeneration (corticobasal degeneration) is a late onset progressive neurodegenerative condition of the 4-repeat-tauopathy-type, classically presenting with asymmetrical rigidity, dystonia and myoclonus.

Methods

We included 397 participants, of which 57.7% were female.

n = 397 participants

Results

younger onset points to Alzheimer's pathology, older onset points away from it

61.8years

CBS-AD

66.1years

CBS-non-AD

More results

The mean age at symptom onset was 65.9 years.

AD biomarkers and pathology permitted classifying 47 (11.8%) of the cases as CBS-AD, 134 (33.8%) as CBS-non-AD and 216 (54.4%) as CBS-indeterminate.

More results

Patients with CBS-AD had higher rates of cortical sensory impairment (P = 0.087) and lower rates of limb dystonia (P < 0.01) and falls (P < 0.01) compared to the CBS-non-AD group.

Volumetric MRI analysis revealed smaller parietal lobe volumes in CBS-AD (P = 0.01).

“

Conclusion

Clinical, imaging and blood-biomarkers in can augment the Armstrong criteria in predicting the underlying pathology of corticobasal syndromes.

Read paper

0 comments

No comments yet. Be the first.

ScholarDeck.

Join the discussion on this paper

Create your profile